A new research article led by BCDI Associate Medical/Research Director Dr. Jonathan Roberts has been published in the Journal of Clinical Medicine. Dr. Roberts was a co-principal investigator in this article entitled “Association of Patient-Reported Outcomes with Hemophilia A Inhibitor Status and Treatment Product Type.” 

In this 85-person study, the article found that participants with active inhibitors experienced joint bleeding rates similar to those of participants without inhibitors, likely attributable to emicizumab use. Tolerized participants reported the fewest joint bleeds and highest quality-of-life scores, potentially reflecting younger age and possible greater prophylaxis adherence. Emicizumab was associated with lower bleed rates compared to standard or extended half-life factor VIII products. These exploratory findings suggest that, in the era of emicizumab, bleeding rates and joint outcomes in patients with active inhibitors may approach those of non-inhibitor patients on prophylaxis.

To learn more about this study or to read the full breakdown, please click here or click on the picture attached above. For a full list of recent BCDI publications and developments from the BCDI Research team, please visit our Recent Publications page.